Peak Retirement Planning Inc. Takes $2.84 Million Position in Hims & Hers Health, Inc. $HIMS

Peak Retirement Planning Inc. bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 50,096 shares of the company’s stock, valued at approximately $2,841,000. Hims & Hers Health accounts for about 0.8% of Peak Retirement Planning Inc.’s portfolio, making the stock its 22nd biggest position.

Several other hedge funds also recently added to or reduced their stakes in HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Hims & Hers Health by 0.8% during the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock worth $1,452,000 after purchasing an additional 200 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Hims & Hers Health by 6.1% in the 3rd quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock valued at $232,000 after buying an additional 236 shares during the last quarter. Concurrent Investment Advisors LLC raised its stake in Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock worth $793,000 after acquiring an additional 252 shares in the last quarter. Bessemer Group Inc. raised its stake in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares in the last quarter. Finally, True Vision MN LLC lifted its position in Hims & Hers Health by 3.6% in the second quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after acquiring an additional 328 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $26.45 on Tuesday. The company has a market capitalization of $6.02 billion, a PE ratio of 48.97, a P/E/G ratio of 4.46 and a beta of 2.37. Hims & Hers Health, Inc. has a 52-week low of $23.97 and a 52-week high of $72.98. The company has a 50-day simple moving average of $34.11 and a 200-day simple moving average of $44.09. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. Hims & Hers Health’s revenue was up 49.2% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has approved a share repurchase plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 3% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Zacks Research downgraded shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. Barclays started coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price for the company. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Bank of America boosted their target price on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $42.62.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the transaction, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 131,974 shares of company stock worth $4,763,800. Insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.